Mueller Brian 4

What Happened

• Brian Mueller, Chief Financial Officer of BioMarin Pharmaceutical (BMRN), had two types of transactions disclosed: a sale of 9,945 shares on March 13, 2026 to cover tax or exercise-related liabilities (proceeds ≈ $581,882 at $58.51/share), and awards granted on March 16, 2026 consisting of 18,740 restricted stock units (RSUs) and a 44,600-unit derivative award (an option grant).
• The March 16 awards were reported at $0.00 per share because they are grants (no cash paid). The derivative award is an option with a multi-year vesting schedule (see Key Details).

Key Details

• Transaction dates and amounts:
  • 2026-03-13: 9,945 shares disposed (tax withholding) at $58.51 = $581,882.
  • 2026-03-16: 18,740 RSUs granted (acquired, no cash).
  • 2026-03-16: 44,600 derivative award (option) granted (acquired, no cash).
• Vesting/terms note: The option grant vests 12/48th on March 16, 2027 and then 1/48th on the 16th of each month thereafter (standard multi-year vesting).
• Shares owned after the reported transactions are not specified in the excerpt provided.
• Footnotes:
  • F1: Confirms the March 16 RSU grant.
  • F2: Reporting holdings were adjusted by two shares to correct a clerical error.
  • F3: Provides the option vesting schedule (see above).
• Filing: Form 4 was filed with accession date 2026-03-17 covering transactions in mid-March 2026. (No late-filing flag was provided in the excerpt.)

Context

• The March 13 sale was a tax-withholding disposal tied to equity compensation and is routine; such transactions are not the same as an intentional open-market sale signaling a view on the stock.
• The March 16 entries are award grants (RSUs and an option). Awards are acquisitions but typically subject to vesting; the option cannot be monetized until it vests and is exercised under its terms.
• As always, insider awards and routine tax-withholding sales are factual disclosures about compensation and do not by themselves indicate future company performance.